Market Overview

UPDATE: BMO Capital Markets Upgrades Merck & Co. to Outperform, Reiterates $50 PT

Share:
Related MRK
Can Keytruda Deliver Earnings Growth For Merck?
Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine
Earnings Bonanza Continues, With Internet, Energy Firms In The Spotlight (Seeking Alpha)

In a report published Monday, BMO Capital Markets upgraded its rating on Merck & Co. (NYSE: MRK) from Market Perform to Outperform, and reiterated its $50.00 price target.

BMO Capital noted, “Merck reported impressive phase-1b data from its Anti-PD-1 cancer immunotherapy, MK-3475, which, similar to BMS'558, also appears very active in melanoma, if not more so, and is well tolerated. Moreover, impressive phase-2 data from the protease inhibitor MK-5172 support its development in an all-oral Hepatitis-C regimen based on its robust activity, once daily dosing, and lack of food effect. Following a good 3Q that showed the value of a broad portfolio coupled with strong execution, and ongoing advances in the pipeline, we believe that a rating upgrade is warranted.”

Merck & Co. closed on Friday at $44.05.

Latest Ratings for MRK

DateFirmActionFromTo
Jul 2016BMO CapitalDowngradesOutperformMarket Perform
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!